Technolas 217z Laser With Zyoptix Aspheric Algorithm Used for the LASIK Treatment of Myopia and Myopic Astigmatism.

Sponsor
Bausch & Lomb Incorporated (Industry)
Overall Status
Completed
CT.gov ID
NCT00769808
Collaborator
(none)
72
1
1
19
3.8

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of the Bausch & Lomb Technolas 217z laser with the investigational Zyoptix Aspheric Algorithm when used for LASIK treatment of myopia and myopic astigmatism.

Condition or Disease Intervention/Treatment Phase
  • Device: Bausch & Lomb 217z Excimer Laser
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
72 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This was a medical device study with only one intervention used for lasik correction surgeryThis was a medical device study with only one intervention used for lasik correction surgery
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Prospective Trial to Evaluate the Safety and Effectiveness of the Bausch & Lomb Technolas® 217z Laser With Zyoptix® Aspheric Algorithm When Used for the LASIK Treatment of Myopia and Myopic Astigmatism
Study Start Date :
Aug 1, 2008
Actual Primary Completion Date :
Mar 1, 2010
Actual Study Completion Date :
Mar 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Experimental: Technolas 217z Excimer Laser

Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism.

Device: Bausch & Lomb 217z Excimer Laser
LASIK correction of myopia and myopic astigmatism

Outcome Measures

Primary Outcome Measures

  1. Percentage of Eyes With Uncorrected High Contrast Distance Visual Acuity of 20/40 or Better [3 months]

  2. Percentage of Eyes With Manifest Subjective Refraction (MRSE) Within ± 1.00 Diopter (D) and 0.50 D of Emmetropia [3 months]

    Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).

  3. Preservation of Manifest Best Corrected High Contrast Distance Visual Acuity [Baseline, 3 months]

    Mean change in best-corrected high contrast distance visual acuity. Corrected means spectacle corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity. Acuity was averaged across visits.

  4. Percentage of Eyes With Manifest Best-corrected Distance Photopic Visual Acuity Decrease of 2 or More Lines [3 months]

  5. Percentage of Eyes With > 2.00 Diopter of Induced Postoperative Refractive Cylinder [3 months]

    Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).

  6. Percentage of Eyes That Had High Contrast Best Spectacle Corrected Visual Acuity (HCBSCVA) of 20/20 or Better at Baseline Had a Visual Outcome Worse Than 20/40 at 3 Months [3 months]

    Corrected means spectacle corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity. Acuity was averaged across visits.

Secondary Outcome Measures

  1. Percentage Change From Baseline in Higher Order Aberrations. [Baseline, 3 months]

    The aberrations in the eye's optical system were measured over the entire pupil by the Bausch & Lomb Zywave II WaveFront Aberrometer, a Hartmann-Shack type device. The pupil should have been at least 6 mm in diameter using 2.5% phenylephrine as a dilating agent to maximize the pupil diameter and hence the amount of wavefront information collected by the Zywave II. The wavefront data was then fitted with Zernike polynomials representing the 2nd, 3rd, 4th and 5th order Zernike terms. These terms represent the wavefront aberration of the eye.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects who were of legal age (at least 18) and had full legal capacity to volunteer.

  • Subjects must be willing to have both eyes treated with the laser.

  • Subjects must have up to -12.00D of absolute spherical myopia (not spherical equivalent) with up to -6.00D of refractive astigmatism, with a spherical equivalent up to -15.00D as measured by manifest subjective refraction.

  • Subjects who had less than 0.75 D of difference in the preoperative manifest spherical equivalent and cycloplegic spherical equivalent subjective refractions.

(Manifest subjective refractions adjusted for optical infinity were used.)

  • High contrast, manifest best spectacle-corrected distance logMAR visual acuity correctable to at least 0.3 in both eyes, and must not differ between eyes by more than 1 line (5 letters).

  • Contact lens wearers must have 2 Orbscan measurements and 2 manifest subjective refractions taken preoperatively at least 1 week apart.

  • Contact lens wearers must have gas permeable lenses discontinued for at least 3 weeks and soft lenses discontinued for at least 2 weeks prior to the preoperative evaluation.

Exclusion

  • Subjects with uncorrected visual acuity better than 20/40 (Snellen) or 0.3 logMAR

  • Subjects who were immuno-compromised or had a diagnosis of connective tissue disease, clinically significant atopic disease, diabetes, autoimmune diseases and other acute or chronic illnesses that increased the risk to the subject or could have confounded the outcomes of this study.

  • Subjects with uncontrolled glaucoma or glaucoma who were under treatment in the study eye or with ocular hypertension.

  • Subjects who demonstrated evidence of retinal vascular disease.

  • Subjects who have an ocular muscle disorder including strabismus or nystagmus, or other disorders that affected fixation.

  • Subjects who were at risk for angle closure or who had a potentially occludable angle, as evidenced by a shallow anterior chamber on slit lamp exam, confirmed by gonioscopy as deemed necessary by the study Investigator.

  • Subjects who had undergone previous intraocular or corneal surgery of any kind, including any type of excimer laser surgery for either refractive or therapeutic purposes.

  • Subjects who were taking systemic medications likely to affect wound healing such as corticosteroids or anti-metabolites or any other medications that may increase the risk to the subject or confound the outcomes of this study.

  • Subjects for whom the combination of their preoperative corneal thickness and the planned operative parameters for the LASIK procedure could have resulted in less than 250 microns of remaining posterior corneal thickness below the flap postoperatively.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lasik MD, 130 King Street Toronto Ontario Canada M5X1C8

Sponsors and Collaborators

  • Bausch & Lomb Incorporated

Investigators

  • Principal Investigator: Mark Cohen, MD, Lasik MD

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier:
NCT00769808
Other Study ID Numbers:
  • 564
First Posted:
Oct 9, 2008
Last Update Posted:
Sep 11, 2020
Last Verified:
Aug 1, 2020
Additional relevant MeSH terms:

Study Results

Participant Flow

Recruitment Details Seventy two myopic participants (144 eyes) were enrolled.
Pre-assignment Detail
Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
Period Title: Overall Study
STARTED 72
COMPLETED 64
NOT COMPLETED 8

Baseline Characteristics

Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
Overall Participants 65
Age (Count of Participants)
<=18 years
0
0%
Between 18 and 65 years
65
100%
>=65 years
0
0%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]
32.0
(7.1)
Sex: Female, Male (Count of Participants)
Female
29
44.6%
Male
36
55.4%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native
0
0%
Asian
21
32.3%
Native Hawaiian or Other Pacific Islander
0
0%
Black or African American
2
3.1%
White
40
61.5%
More than one race
0
0%
Unknown or Not Reported
2
3.1%

Outcome Measures

1. Primary Outcome
Title Percentage of Eyes With Uncorrected High Contrast Distance Visual Acuity of 20/40 or Better
Description
Time Frame 3 months

Outcome Measure Data

Analysis Population Description
There were 59 participants with visual acuity data available for analysis.
Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
Measure Participants 59
Measure eyes 118
Number (95% Confidence Interval) [percentage of eyes]
99.2
2. Primary Outcome
Title Percentage of Eyes With Manifest Subjective Refraction (MRSE) Within ± 1.00 Diopter (D) and 0.50 D of Emmetropia
Description Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).
Time Frame 3 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
Measure Participants 59
Measure eyes 118
Within 0.50 D
109
Within 1.00 D
117
3. Primary Outcome
Title Preservation of Manifest Best Corrected High Contrast Distance Visual Acuity
Description Mean change in best-corrected high contrast distance visual acuity. Corrected means spectacle corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity. Acuity was averaged across visits.
Time Frame Baseline, 3 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
Measure Participants 59
Measure eyes 118
Mean (Standard Deviation) [units on a scale]
-0.055
(0.103)
4. Primary Outcome
Title Percentage of Eyes With Manifest Best-corrected Distance Photopic Visual Acuity Decrease of 2 or More Lines
Description
Time Frame 3 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
Measure Participants 59
Measure eyes 118
Count of Units [eyes]
1
5. Primary Outcome
Title Percentage of Eyes With > 2.00 Diopter of Induced Postoperative Refractive Cylinder
Description Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis. Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina. Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder. It is expressed in diopters (D).
Time Frame 3 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
Measure Participants 59
Measure eyes 118
Count of Units [eyes]
0
6. Primary Outcome
Title Percentage of Eyes That Had High Contrast Best Spectacle Corrected Visual Acuity (HCBSCVA) of 20/20 or Better at Baseline Had a Visual Outcome Worse Than 20/40 at 3 Months
Description Corrected means spectacle corrected. Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters were recorded. A decrease in the number of correct letters indicates a decrease in visual acuity. Acuity was averaged across visits.
Time Frame 3 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
Measure Participants 59
Measure eyes 118
Count of Units [eyes]
0
7. Secondary Outcome
Title Percentage Change From Baseline in Higher Order Aberrations.
Description The aberrations in the eye's optical system were measured over the entire pupil by the Bausch & Lomb Zywave II WaveFront Aberrometer, a Hartmann-Shack type device. The pupil should have been at least 6 mm in diameter using 2.5% phenylephrine as a dilating agent to maximize the pupil diameter and hence the amount of wavefront information collected by the Zywave II. The wavefront data was then fitted with Zernike polynomials representing the 2nd, 3rd, 4th and 5th order Zernike terms. These terms represent the wavefront aberration of the eye.
Time Frame Baseline, 3 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
Measure Participants 59
Measure eyes 118
Mean (Standard Deviation) [Percentage change]
24.9
(0.1413)

Adverse Events

Time Frame 6 months
Adverse Event Reporting Description There were 66 treated participants evaluated for adverse events.
Arm/Group Title Technolas 217z Excimer Laser
Arm/Group Description Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism. Bausch & Lomb 217z Excimer Laser: LASIK correction of myopia and myopic astigmatism
All Cause Mortality
Technolas 217z Excimer Laser
Affected / at Risk (%) # Events
Total 0/66 (0%)
Serious Adverse Events
Technolas 217z Excimer Laser
Affected / at Risk (%) # Events
Total 0/66 (0%)
Other (Not Including Serious) Adverse Events
Technolas 217z Excimer Laser
Affected / at Risk (%) # Events
Total 51/66 (77.3%)
Eye disorders
Bowman's membrane disorder 8/66 (12.1%)
Corneal edema 4/66 (6.1%)
Keratitis 16/66 (24.2%)
Punctate keratitis 36/66 (54.5%)
Eye operation complication 21/66 (31.8%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

Results Point of Contact

Name/Title Study Director
Organization Bausch & Lomb Incorporated
Phone 9083009926
Email susan.harris@bauschhealth.com
Responsible Party:
Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier:
NCT00769808
Other Study ID Numbers:
  • 564
First Posted:
Oct 9, 2008
Last Update Posted:
Sep 11, 2020
Last Verified:
Aug 1, 2020